PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA; Division of Research, Kaiser Permanente Northern California, Oakland, CA. Electronic address: andrew.p.ambrosy@kp.org.\', \'Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA.\', \'Division of Research, Kaiser Permanente Northern California, Oakland, CA.\', \'Division of Research, Kaiser Permanente Northern California, Oakland, CA; Department of Cardiology, Kaiser Permanente Oakland Medical Center, Oakland, CA.\', \'Department of Cardiology, Kaiser Permanente Walnut Creek Medical Center, Walnut Creek, CA.\', \'Division of Research, Kaiser Permanente Northern California, Oakland, CA; Department of Infectious Disease, Kaiser Permanente Oakland Medical Center, Oakland, CA.\', \'Amarin Pharma, Inc., Bridgewater, NJ.\', \'Brigham and Women\'s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA.\', \'Division of Research, Kaiser Permanente Northern California, Oakland, CA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA; Departments of Medicine (Nephrology), Epidemiology, and Biostatistics, University of California, San Francisco, San Francisco, CA; Department of Medicine (Nephrology), Stanford University, Palo Alto, CA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0002-8703(21)00031-410.1016/j.ahj.2021.01.018
?:hasPublicationType
?:journal
  • American heart journal
is ?:pmid of
?:pmid
?:pmid
  • 33516752
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 3.267
?:rankingScore_hIndex
  • 169
is ?:relation_isRelatedTo_publication of
?:title
  • Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE).
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all